Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference
AL Ross, A Bråve, G Scarlatti, A Manrique… - The Lancet infectious …, 2010 - thelancet.com
The search for an HIV/AIDS vaccine is steadily moving ahead, generating and validating new
concepts in terms of novel vectors for antigen delivery and presentation, new vaccine and …
concepts in terms of novel vectors for antigen delivery and presentation, new vaccine and …
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
…, B Joos, M Fischer, C Leemann, A Manrique… - Nature medicine, 2005 - nature.com
To determine the protective potential of the humoral immune response against HIV-1 in vivo
we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in …
we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in …
RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement
B Roscic-Mrkic, M Fischer, C Leemann, A Manrique… - Blood, 2003 - ashpublications.org
The CC-chemokine RANTES (regulated on activation normal T-cell expressed and secreted;
CCL5) transduces multiple intracellular signals. Like all chemokines, it stimulates G protein…
CCL5) transduces multiple intracellular signals. Like all chemokines, it stimulates G protein…
[HTML][HTML] Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection
M Huber, M Fischer, B Misselwitz, A Manrique… - PLoS …, 2006 - journals.plos.org
Background To explore the possibility that antibody-mediated complement lysis contributes
to viremia control in HIV-1 infection, we measured the activity of patient plasma in mediating …
to viremia control in HIV-1 infection, we measured the activity of patient plasma in mediating …
In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10
A Manrique, P Rusert, B Joos, M Fischer… - Journal of …, 2007 - Am Soc Microbiol
Recently, passive immunization of human immunodeficiency virus (HIV)-infected individuals
with monoclonal antibodies (MAbs) 2G12, 2F5, and 4E10 provided evidence of the in vivo …
with monoclonal antibodies (MAbs) 2G12, 2F5, and 4E10 provided evidence of the in vivo …
[HTML][HTML] High efficacy of saliva in detecting SARS-CoV-2 by RT-PCR in adults and children
Rising demands for repetitive SARS-CoV-2 screens and mass testing necessitate additional
test strategies. Saliva may serve as an alternative to nasopharyngeal swab (NPS) as its …
test strategies. Saliva may serve as an alternative to nasopharyngeal swab (NPS) as its …
Molecular characterization of a novel lipase-like pathogen-inducible gene family of Arabidopsis
In a differential screening between Arabidopsis plants pretreated with the resistance-inducer
β-aminobutyric acid and untreated control plants, we have identified a gene encoding a …
β-aminobutyric acid and untreated control plants, we have identified a gene encoding a …
The future of HIV vaccine research and the role of the Global HIV Vaccine Enterprise
Y Voronin, A Manrique, A Bernstein - Current Opinion in HIV and …, 2010 - journals.lww.com
This time is an important moment in HIV vaccine research. New clinical trial and laboratory
results have created new opportunities to advance the search for an HIV vaccine and …
results have created new opportunities to advance the search for an HIV vaccine and …
[HTML][HTML] Reduced relative sensitivity of the elecsys SARS-CoV-2 antigen assay in saliva compared to nasopharyngeal swabs
Early identification and isolation of SARS-CoV-2-infected individuals is central to contain the
COVID-19 pandemic. Nasopharyngeal swabs (NPS) serve as a specimen for detection by …
COVID-19 pandemic. Nasopharyngeal swabs (NPS) serve as a specimen for detection by …
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
…, S Rueegg, S Epp, C Berger, J Böni, A Manrique… - Mbio, 2024 - Am Soc Microbiol
Numerous clinical parameters link to severe coronavirus disease 2019, but factors that
prevent symptomatic disease remain unknown. We investigated the impact of severe acute …
prevent symptomatic disease remain unknown. We investigated the impact of severe acute …